148 related articles for article (PubMed ID: 34216526)
1. Reply to 'Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B'-A reply.
Liu Y
J Viral Hepat; 2021 Oct; 28(10):1502. PubMed ID: 34216526
[No Abstract] [Full Text] [Related]
2. Reply to 'Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B'.
Kamalapirat T; Ungtrakul T
J Viral Hepat; 2021 Oct; 28(10):1501. PubMed ID: 34219333
[No Abstract] [Full Text] [Related]
3. Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B.
Liu Y
J Viral Hepat; 2021 Oct; 28(10):1500. PubMed ID: 34216528
[No Abstract] [Full Text] [Related]
4. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B-authors' reply.
Kim GA; Lim YS
Aliment Pharmacol Ther; 2021 Mar; 53(6):763. PubMed ID: 33599320
[No Abstract] [Full Text] [Related]
5. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply.
Lee HA; Kim SU
Aliment Pharmacol Ther; 2020 Sep; 52(5):913-914. PubMed ID: 32852833
[No Abstract] [Full Text] [Related]
6. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Huang R; Liu J; Wang J; Yan X; Wu C
Aliment Pharmacol Ther; 2021 Mar; 53(6):761-762. PubMed ID: 33599329
[No Abstract] [Full Text] [Related]
7. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B.
Gattani M; Ingle M; Chauhan S; Lad S
Aliment Pharmacol Ther; 2020 Sep; 52(5):911-912. PubMed ID: 32852812
[No Abstract] [Full Text] [Related]
8. Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Chang JW; Kim SU
J Viral Hepat; 2021 Mar; 28(3):574. PubMed ID: 33305419
[No Abstract] [Full Text] [Related]
9. Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Liu Y; Mo Y; Wu A
J Viral Hepat; 2021 Mar; 28(3):573. PubMed ID: 33264447
[No Abstract] [Full Text] [Related]
10. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous Seroclearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma.
Song C; Zhu J; Ge Z; Yu C; Tian T; Wang H; Han J; Shen H; Dai J; Lu J; Hu Z
Clin Gastroenterol Hepatol; 2019 May; 17(6):1204-1206. PubMed ID: 30114488
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
Chun HS; Lee M
Clin Mol Hepatol; 2021 Jul; 27(3):448-450. PubMed ID: 34157831
[No Abstract] [Full Text] [Related]
13. [Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection].
Expert Group for Project of Hepatocellular Carcinoma Screening and Surveillance, Chinese Foundation for Hepatitis Prevention and Control
Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):932-941. PubMed ID: 34814387
[TBL] [Abstract][Full Text] [Related]
14. Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
Chan HL; Wong VW; Yip TC; Wong GL
J Hepatol; 2020 Sep; 73(3):729-730. PubMed ID: 32423634
[No Abstract] [Full Text] [Related]
15. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
16. Letter to the editor: Hepatitis B virus genotype: A significant risk factor in determining which patients with chronic hepatitis B virus infection should undergo surveillance for hepatocellular carcinoma: The hepatitis B Alaska study.
Kumar A; Rajani D; Kumar S
Hepatology; 2022 Sep; 76(3):E63-E64. PubMed ID: 35478185
[No Abstract] [Full Text] [Related]
17. Association between Hepatitis B Surface Antigen Levels and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection: Systematic Review and Meta-Analysis.
Thi Vo T; Poovorawan K; Charoen P; Soonthornworasiri N; Nontprasert A; Kittitrakul C; Phumratanaprapin W; Tangkijvanich P
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2239-2246. PubMed ID: 31450890
[TBL] [Abstract][Full Text] [Related]
18. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection.
Wen WH; Chang MH; Hsu HY; Ni YH; Chen HL
J Pediatr; 2004 Mar; 144(3):397-9. PubMed ID: 15001956
[TBL] [Abstract][Full Text] [Related]
19. Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?
Howell J; Chan HLY; Feld JJ; Hellard ME; Thompson AJ
Gastroenterology; 2020 Jun; 158(8):2028-2032. PubMed ID: 32088205
[No Abstract] [Full Text] [Related]
20. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
